Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?
2026-07-20 07:15
•Prosper Junior Bakiny •The Motley Fool
•••••• •••• Axe Capital view
Pfizer's weight-loss play: Not top dog, but a solid contender
Pfizer’s growing appetite in weight-loss drugs adds a new dimension to its diversified JSE-friendly profile.
South African investors often overlook Pfizer because it’s a giant US pharma name, but its strategic entry into the $100 billion weight-loss drug market deserves a second look. Pfizer’s MET-097i shows promising clinical results with a potential monthly dosing edge, which could appeal to patient convenience—a factor sometimes undervalued in this space. That said, leaders like Eli Lilly and Novo Nordisk remain ahead with more advanced triple agonists mimicking bariatric surgery outcomes. For the local market, Pfizer’s appeal comes from its robust dividend yield near 7%, plus growth in oncology, which balances patent cliff risks. For rand investors, Pfizer offers some shelter when global risk appetite sours, as it’s a high-quality non-cyclical name. The risk? The weight-loss market may consolidate around the current winners, leaving Pfizer in a niche position. Also, currency swings in USD/ZAR can bite returns. Still, given its mix of yield and pipeline, Pfizer is worth watching, especially as other local defensive plays like Sanlam and MTN trade with higher volatility. this is just my opinion and not financial advice
Buy selective US pharma exposure like Pfizer through global ETFs or ADRs if you want income and growth balance, but keep position size modest and hedge rand risk. Avoid chasing pure weight-loss specialists until clinical differentiation is clearer.
- PFE
- USD/ZAR
- market consolidates around Eli Lilly and Novo Nordisk
- rand weakness erodes returns
6/10
Pfizer is positioning itself as a contender in the rapidly growing $100 billion weight-loss drug market through its acquisition of Metsera and development of promising GLP-1 candidates like MET-097i, which showed strong efficacy with potential monthly dosing. However, the company faces stiff competition from Eli Lilly and Novo Nordisk, who currently lead the market with more advanced triple agonist drugs. While Pfizer may not dominate the space, it is well-positioned to be a significant player, and the company has other growth drivers including oncology pipeline and a high dividend yield of 6.9%.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Prosper Junior Bakiny
Categories: Rates, Equities, Earnings, M&A, Capital Returns, Healthcare
Tickers: PFE, LLY, NVO, AMGN
Sentiment: Positive - Pfizer has a promising weight-loss pipeline with MET-097i showing strong clinical results and potential monthly dosing advantage. The company also offers an attractive 6.9% dividend yield and has other growth drivers in oncology, making it a solid investment despite competitive pressures. Eli Lilly is identified as the current market leader with retatrutide, a next-generation triple agonist drug showing impressive phase 3 results rivaling bariatric surgery outcomes. The author explicitly states this would be their top pick in the weight-loss market.
Keywords: weight-loss drugs, GLP-1 medicine, pharmaceutical pipeline, obesity market, patent cliff, clinical trials, dividend stocks
Insights:
- PFE: Positive: Pfizer has a promising weight-loss pipeline with MET-097i showing strong clinical results and potential monthly dosing advantage. The company also offers an attractive 6.9% dividend yield and has other growth drivers in oncology, making it a solid investment despite competitive pressures.
- LLY: Positive: Eli Lilly is identified as the current market leader with retatrutide, a next-generation triple agonist drug showing impressive phase 3 results rivaling bariatric surgery outcomes. The author explicitly states this would be their top pick in the weight-loss market.
- NVO: Positive: Novo Nordisk is a leading competitor with multiple triple agonists in its pipeline and recent encouraging mid-stage results. The company benefits from decades of dominance in the adjacent diabetes market.